Efficacy of Adalimumab in Non-Infectious Uveitis Across Different Etiologies: A Post Hoc Analysis of the VISUAL I and VISUAL II Trials

Abstract

Purpose: To assess efficacy of adalimumab versus placebo in patients with active or inactive noninfectious intermediate, posterior, or panuveitis across different etiologies. Methods: VISUAL I (V–I) and VISUAL II (V–II) clinical trials included adults with active or inactive uveitis, respectively, randomized to receive adalimumab or placebo. In a post hoc subgroup analysis, time to treatment failure (TTF) starting at week 6 (V–I) or week 2 (V–II) was analyzed using the Kaplan–Meier method. Hazard ratios (HR) for TTF with 95% CI were calculated with Cox proportional hazards regression. Results: The analysis included 217 V–I patients and 226 V–II patients. Treatment failure occurred later and risk was significantly lower in patients with idiopathic uveitis receiving adalimumab versus those receiving placebo in V–I (HR = 0.50 [CI, 0.30–0.84]; P = .006) and V–II (HR = 0.43 [CI, 0.22–0.83]; P = .010). Conclusions: Treatment failure risk was lower in patients with idiopathic noninfectious uveitis receiving adalimumab versus those receiving placebo.